Angel is a Vice President on the Frazier Life Sciences team and focuses on identifying and evaluating new investment opportunities.
Angel joined Frazier Life Sciences in 2021 and focuses on evaluating investment opportunities in the life sciences sector. She contributed to Frazier’s investment in Sonoma Biotherapeutics and is a board observer at Sonoma Biotherapeutics, Alesta Therapeutics and V6 Therapeutics.
Prior to joining Frazier, Angel was an Investment Fellow with Vertex Ventures Healthcare. At Vertex, she evaluated early-stage companies pursuing transformative therapeutics. In previous roles, Angel served as the Director of Research and Venture Grants at Emerson Collective, Health and as the Research Director of the Friedreich Ataxia (FA) Research Alliance. In these roles, she managed strategic deployment of capital towards emergent therapeutics for oncology and FA, respectively.
Angel received her Ph.D. in Pharmacology and Cancer Biology from Duke University, where she was a Ruth L. Kirschstein Institutional National Research Service Award Fellow of the National Heart, Lung and Blood Institute.
San Diego
Duke University (Ph.D.)
University of Michigan, Ann Arbor (B.A.)
2021
1001 Page Mill Road
Building 4, Suite 200B
Palo Alto, CA 94304
650-325-5156
11455 El Camino Real, Suite 470
San Diego, CA 92130
100 Federal Street, 19th Floor
Boston, MA 02110
1700 Seventh Ave, Suite 1120
Seattle, WA 98101
